Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Total Liabilities (2019 - 2026)

Biodesix filings provide 8 years of Total Liabilities readings, the most recent being $85.5 million for Q1 2026.

  • On a quarterly basis, Total Liabilities rose 13.73% to $85.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $85.5 million, a 13.73% increase, with the full-year FY2025 number at $89.9 million, up 17.77% from a year prior.
  • Total Liabilities hit $85.5 million in Q1 2026 for Biodesix, down from $89.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $94.5 million in Q4 2023 to a low of $53.9 million in Q1 2022.
  • Median Total Liabilities over the past 5 years was $79.6 million (2024), compared with a mean of $79.7 million.
  • Biggest five-year swings in Total Liabilities: crashed 31.86% in 2022 and later skyrocketed 41.53% in 2023.
  • Biodesix's Total Liabilities stood at $72.3 million in 2022, then soared by 30.73% to $94.5 million in 2023, then fell by 19.2% to $76.4 million in 2024, then increased by 17.77% to $89.9 million in 2025, then fell by 4.93% to $85.5 million in 2026.
  • The last three reported values for Total Liabilities were $85.5 million (Q1 2026), $89.9 million (Q4 2025), and $90.4 million (Q3 2025) per Business Quant data.